M

MoonLake Immunotherapeutics
NASDAQ:MLTX

Watchlist Manager
MoonLake Immunotherapeutics
NASDAQ:MLTX
Watchlist
Price: 51.89 USD -1.35% Market Closed
Market Cap: 3.3B USD
Have any thoughts about
MoonLake Immunotherapeutics?
Write Note

Profitability Summary

MoonLake Immunotherapeutics's profitability score is 42/100. We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

42/100
Profitability
Score

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

42/100
Profitability
Score
42/100
Profitability
Score
High Profitability Stocks

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
MoonLake Immunotherapeutics

Revenue
0 USD
Operating Expenses
-108.5m USD
Operating Income
-108.5m USD
Other Expenses
27.8m USD
Net Income
-80.8m USD

Margins Comparison
MoonLake Immunotherapeutics Competitors

Country CH
Market Cap 3.3B USD
Operating Margin N/A
Net Margin N/A
Country CA
Market Cap 559.6B CAD
Operating Margin N/A
Net Margin N/A
Country IN
Market Cap 9.7T INR
Operating Margin
8%
Net Margin
-59%
Country US
Market Cap 89B USD
Operating Margin
1%
Net Margin
4%
Country NL
Market Cap 84.2B Zac
Operating Margin
61%
Net Margin
63%
Country ID
Market Cap 690.7T IDR
Operating Margin
38%
Net Margin
12%
Country US
Market Cap 41B EUR
Operating Margin
1%
Net Margin
4%
Country IN
Market Cap 2T INR
Operating Margin
68%
Net Margin
123%
Country CH
Market Cap 20.2B CHF
Operating Margin
15%
Net Margin
-1%
Country US
Market Cap 22.3B USD
Operating Margin
-54%
Net Margin
-48%
Country ZA
Market Cap 19.8B Zac
Operating Margin
52%
Net Margin
99%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
MoonLake Immunotherapeutics Competitors

Country Company Market Cap ROE ROA ROCE ROIC
CH
MoonLake Immunotherapeutics
NASDAQ:MLTX
3.3B USD
-18%
-16%
-22%
-1 431%
CA
Advance Lithium Corp
XTSX:AALI
559.6B CAD
-192%
-148%
-35%
-34%
IN
SAB Industries Ltd
BSE:539112
9.7T INR
-13%
-7%
1%
1%
US
GE Vernova LLC
NYSE:GEV
89B USD
11%
2%
2%
1%
NL
Nepi Rockcastle NV
JSE:NRP
84.2B Zac
12%
7%
7%
6%
ID
Amman Mineral Internasional Tbk PT
IDX:AMMN
690.7T IDR
6%
3%
9%
8%
US
Coupang Inc
F:788
41B EUR
29%
7%
5%
27%
IN
Jio Financial Services Ltd
NSE:JIOFIN
2T INR
1%
1%
1%
1%
CH
Galderma Group AG
SIX:GALD
20.2B CHF N/A N/A N/A N/A
US
Reddit Inc
NYSE:RDDT
22.3B USD
-32%
-29%
-36%
-184%
ZA
Fortress Real Estate Investments Ltd
JSE:FFB
19.8B Zac
14%
8%
5%
3%
Country CH
Market Cap 3.3B USD
ROE
-18%
ROA
-16%
ROCE
-22%
ROIC
-1 431%
Country CA
Market Cap 559.6B CAD
ROE
-192%
ROA
-148%
ROCE
-35%
ROIC
-34%
Country IN
Market Cap 9.7T INR
ROE
-13%
ROA
-7%
ROCE
1%
ROIC
1%
Country US
Market Cap 89B USD
ROE
11%
ROA
2%
ROCE
2%
ROIC
1%
Country NL
Market Cap 84.2B Zac
ROE
12%
ROA
7%
ROCE
7%
ROIC
6%
Country ID
Market Cap 690.7T IDR
ROE
6%
ROA
3%
ROCE
9%
ROIC
8%
Country US
Market Cap 41B EUR
ROE
29%
ROA
7%
ROCE
5%
ROIC
27%
Country IN
Market Cap 2T INR
ROE
1%
ROA
1%
ROCE
1%
ROIC
1%
Country CH
Market Cap 20.2B CHF
ROE N/A
ROA N/A
ROCE N/A
ROIC N/A
Country US
Market Cap 22.3B USD
ROE
-32%
ROA
-29%
ROCE
-36%
ROIC
-184%
Country ZA
Market Cap 19.8B Zac
ROE
14%
ROA
8%
ROCE
5%
ROIC
3%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More
Back to Top